Afshar Hezarkhani Leila, Veysi Kazhal, Rahmani Adibeh, Salari Nader, Hasheminezhad Razie, Nasr Vahideh, Mohammadi Masoud
From the Neuroscience Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Medical Biology Research Centre, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Cardiol Rev. 2024 Feb 15. doi: 10.1097/CRD.0000000000000671.
Neurological diseases, including ischemic stroke, are considered a big challenge for public health due to their high prevalence and lack of definitive and effective treatments. Addressing these issues requires innovative therapeutic approaches and among the limited methods available, stem cells have shown promise in improving central nervous system repair by enhancing myelin regeneration and neuronal recovery. To advance this field of research, this systematic review aims to assess the safety and effectiveness of mesenchymal stem cells (MSCs) derived from both bone marrow and adipose tissue for the treatment of ischemic stroke. This study conducted a systematic review in the electronic databases PubMed, Scopus, Web of Science, Embase, ScienceDirect, and Google Scholar to assess the efficacy and safety of MSCs generated from bone marrow and adipose tissue for the treatment of ischemic stroke. It was extracted without a time limit until April 2023. The studies were then transferred to the information management program (EndNote) and duplicates were eliminated. The remaining studies were then examined using the entry and exit criteria and the 3 stages of primary, secondary, and qualitative evaluation, and finally, the results of the final studies were extracted. According to the initial search in the desired databases, 1028 possible related articles were identified and transferred to the information management software (EndNote). After removing 390 duplicate studies, 608 studies were excluded based on inclusion and exclusion criteria. Finally, 37 final studies were included in the systematic review process. Based on the investigations, it was evident that the administration of MSCs derived from both bone marrow and adipose tissue holds significant promise as an effective and safe treatment approach for ischemic stroke. The results consistently showed acceptable outcomes in the studies and this evidence can be recommended for the clinical application of this treatment. Also, the findings of this study report that the use of adipose tissue and bone marrow MSCs in the treatment of ischemic stroke can be used as a practical method.
包括缺血性中风在内的神经系统疾病,因其高发病率以及缺乏明确有效的治疗方法,被视为公共卫生领域的一大挑战。解决这些问题需要创新的治疗方法,在现有的有限方法中,干细胞已显示出通过促进髓鞘再生和神经元恢复来改善中枢神经系统修复的潜力。为推动该研究领域的发展,本系统评价旨在评估源自骨髓和脂肪组织的间充质干细胞(MSC)治疗缺血性中风的安全性和有效性。本研究在电子数据库PubMed、Scopus、Web of Science、Embase、ScienceDirect和谷歌学术中进行了系统评价,以评估源自骨髓和脂肪组织的MSC治疗缺血性中风的疗效和安全性。提取时间不限,截至2023年4月。然后将这些研究转移到信息管理程序(EndNote)中,并消除重复项。随后使用纳入和排除标准以及初级、次级和定性评估的三个阶段对其余研究进行审查,最后提取最终研究的结果。根据在目标数据库中的初步搜索,共识别出1028篇可能相关的文章,并转移到信息管理软件(EndNote)中。在去除390项重复研究后,根据纳入和排除标准排除了608项研究。最后,37项最终研究被纳入系统评价过程。基于这些调查,显然源自骨髓和脂肪组织的MSC给药作为缺血性中风的一种有效且安全的治疗方法具有重大前景。研究结果在各项研究中始终显示出可接受的结果,这一证据可推荐用于该治疗方法的临床应用。此外,本研究的结果报告称,使用脂肪组织和骨髓MSC治疗缺血性中风可作为一种实用方法。